Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
Arthritis Res Ther
; 21(1): 122, 2019 05 21.
Article
em En
| MEDLINE
| ID: mdl-31113455
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Imunoglobulina G
/
Receptores do Fator de Necrose Tumoral
/
Antirreumáticos
/
Medicamentos Biossimilares
/
Etanercepte
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Arthritis Res Ther
Ano de publicação:
2019
Tipo de documento:
Article